New York State Common Retirement Fund decreased its holdings in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 43.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,456 shares of the medical instruments supplier's stock after selling 28,003 shares during the quarter. New York State Common Retirement Fund owned approximately 0.07% of STAAR Surgical worth $886,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creative Planning lifted its stake in shares of STAAR Surgical by 8.0% during the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier's stock worth $205,000 after buying an additional 408 shares during the last quarter. Van ECK Associates Corp raised its holdings in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock valued at $129,000 after acquiring an additional 393 shares during the period. Kornitzer Capital Management Inc. KS lifted its position in STAAR Surgical by 1.2% during the third quarter. Kornitzer Capital Management Inc. KS now owns 164,625 shares of the medical instruments supplier's stock worth $6,116,000 after acquiring an additional 1,900 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in STAAR Surgical during the third quarter worth approximately $409,000. Finally, Los Angeles Capital Management LLC boosted its holdings in shares of STAAR Surgical by 78.3% during the third quarter. Los Angeles Capital Management LLC now owns 16,474 shares of the medical instruments supplier's stock worth $612,000 after acquiring an additional 7,237 shares during the period. 96.70% of the stock is owned by institutional investors.
Insider Buying and Selling
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the stock in a transaction dated Wednesday, December 18th. The stock was bought at an average price of $24.33 per share, with a total value of $559,590.00. Following the acquisition, the insider now owns 10,848,631 shares of the company's stock, valued at approximately $263,947,192.23. This represents a 0.21 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have bought 910,843 shares of company stock worth $15,509,972. Corporate insiders own 1.00% of the company's stock.
STAAR Surgical Trading Up 4.4 %
STAAR Surgical stock traded up $0.79 during trading hours on Friday, reaching $18.71. 810,902 shares of the stock were exchanged, compared to its average volume of 1,097,455. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The company has a market cap of $922.62 million, a P/E ratio of -45.62 and a beta of 0.66. The stock has a 50 day moving average of $21.27 and a two-hundred day moving average of $26.98.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. William Blair cut STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Stephens reissued an "equal weight" rating and issued a $28.00 target price on shares of STAAR Surgical in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group dropped their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $26.86.
View Our Latest Analysis on STAAR Surgical
STAAR Surgical Company Profile
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Further Reading
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
